Abstract
Over the past decade there has been significant advancement in the systemic therapy of non-small cell lung cancer, especially in the metastatic setting. More recently, medications which have been proven in advanced disease have been shown to provide benefit in the adjuvant setting as well. We review two recent trials which have studied the use of EGFR-targeted therapies and checkpoint inhibitor therapies in patients who have undergone surgical therapy for resectable disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
